In January 2019, Bristol-Myers Squibb and Celgene Corporation announced that they had entered into a definitive merger agreement for BMS to acquire Celgene for $74 billion. If approved the transaction will create the leading specialty biopharma company addressing the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease. Since announcement of the merger, it has been a daily topic in business and industry news.
There is a concern that the merger of these two dominant players could lead to a decrease in competition, especially in the field of cancer drugs. Several Members of Congress have already urged both the Federal Trade Commission and the Department of Justice to carefully examine its impact on competition and consumer prices. Thus, the specter of an FTC and/or DOJ investigation leaves open remains, with questions what the combined company, and the industry will look like after the merger.
Join Gene Quinn, President & CEO of IPWatchdog, Inc., for a free webinar on Monday, February 11, 2019. Joining Mr. Quinn will be Marco Richter, LexisNexis PatentSight.
In addition to answering as many questions as we can, the presenters will discuss:
- The proposed BMS acquisition of Celgene along with the forces behind and the potential divesture scenarios to see how the technology landscape will be affected;
- The effect of M&As on the innovation landscape is becoming more important for policy makers;
- Lessons from decisions in the Dow/DuPont merger and how these might impact Bristol-Myers Squibb;
- The impact of advanced patent analytics for informing competition analysis and how to model divestiture scenarios and their effect on the technology landscape.
- How to spot acquisition targets and analyze future M&A scenarios.